🇺🇸 SELLAS Life Sciences Group, Inc.SLS

Company Update Form 8-K 17-11-2026 07:14:19 EST

Subject: 8-K Items 7.01, 8.01, 9.01

Overview: Announced positive Phase 3 REGAL trial results for galinpepimut-S, showing a 41% reduction in death risk and median overall survival of 24.0 months.

Source: SEC EDGAR · Original filing

Open document in a new tab

Get filings like this in Telegram the moment they are published — for the companies you follow.

Start 30-day trial About Finterest